Serological biomarkers of candidemia: a retrospective evaluation of three assays.
BDG
Beta-D-glucan
Candidemia
Mannan
Serology
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
23
08
2018
accepted:
19
09
2018
pubmed:
29
9
2018
medline:
6
7
2019
entrez:
29
9
2018
Statut:
ppublish
Résumé
Serologic testing allows for rapid detection of candidemia. More data are needed for the Virion\Serion ELISA antigen test (Ag), Hemkit Candida IHA antibody test (Ab), and Wako β-1,3-D-glucan assay (BDG). Tests were performed on serum samples from 120 cases of culture-confirmed candidemia and 44 Candida-negative controls. Sensitivities and specificities of individual tests as well as combinations were assessed. The overall sensitivity of Ag, Ab, and Ag/Ab testing was 30, 40, and 54%, respectively, while in transplant patients it significantly dropped to 16, 26, and 40% (p = 0.02). For BDG testing it was 67%, both overall and in transplant patients. Especially Ag testing performed poorly among women ≤ 65 years with a significantly reduced sensitivity of 9% (p < 0.002). While the sensitivity of Ag/Ab testing was somewhat higher at 67% for C. albicans, it was significantly lower for non-albicans species at 42% (p = 0.006). The sensitivity of BDG testing for C. albicans and non-albicans species was not significantly different at 64 and 69%, respectively. Both Ag/Ab and BDG testing had a high specificity of 93%, for Ag testing it was 100%. Similar sensitivities were calculated for sera sampled on the day of and 4-6 days before sampling of positive blood cultures. Serological markers are valuable tools for the early diagnosis of candidemia. Ab, Ag, and BDG testing are all characterized by high specificity. The Wako BDG test is significantly more sensitive compared to combined Candida-Ag/Ab testing, particularly in the setting of non-albicans species and specific host factors.
Identifiants
pubmed: 30264200
doi: 10.1007/s15010-018-1224-3
pii: 10.1007/s15010-018-1224-3
doi:
Substances chimiques
Biomarkers
0
Reagent Kits, Diagnostic
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
217-224Références
J Clin Microbiol. 1999 May;37(5):1510-7
pubmed: 10203514
Eur J Clin Microbiol Infect Dis. 2001 Dec;20(12):864-70
pubmed: 11837637
J Med Microbiol. 2002 May;51(5):433-42
pubmed: 11990496
Clin Infect Dis. 2004 Aug 1;39(3):309-17
pubmed: 15306996
Crit Care Med. 2006 Mar;34(3):730-7
pubmed: 16505659
Clin Microbiol Rev. 2007 Jan;20(1):133-63
pubmed: 17223626
Clin Infect Dis. 2008 Jun 15;46(12):1813-21
pubmed: 18462102
Diagn Microbiol Infect Dis. 2009 Aug;64(4):408-15
pubmed: 19631094
J Clin Microbiol. 2011 Jan;49(1):325-34
pubmed: 20980569
Crit Care. 2010;14(6):R222
pubmed: 21143834
Clin Infect Dis. 2011 Mar 15;52(6):750-70
pubmed: 21367728
Mycoses. 2011 Nov;54(6):467-74
pubmed: 21535452
FEMS Microbiol Rev. 2012 Mar;36(2):288-305
pubmed: 21569057
J Clin Microbiol. 2012 Jan;50(1):7-15
pubmed: 22075593
Intern Med. 2011;50(22):2783-91
pubmed: 22082890
Scand J Infect Dis. 2012 Aug;44(8):600-4
pubmed: 22385270
Clin Infect Dis. 2012 Apr;54(8):1110-22
pubmed: 22412055
Clin Infect Dis. 2012 Jun;54(12):1739-46
pubmed: 22423135
Clin Microbiol Infect. 2012 Dec;18 Suppl 7:9-18
pubmed: 23137134
Clin Infect Dis. 2013 May;56(9):1284-92
pubmed: 23315320
J Clin Microbiol. 2013 Apr;51(4):1158-64
pubmed: 23363830
J Clin Microbiol. 2013 Dec;51(12):4167-72
pubmed: 24108614
Intensive Care Med. 2014 Jun;40(6):839-45
pubmed: 24807083
Ther Adv Infect Dis. 2014 Oct;2(5-6):105-15
pubmed: 25745560
Clin Infect Dis. 2016 Feb 15;62(4):e1-50
pubmed: 26679628
Arch Pathol Lab Med. 2016 Feb;140(2):181-5
pubmed: 26910223
J Clin Microbiol. 2018 Apr 25;56(5):
pubmed: 29444828
J Clin Microbiol. 2018 Aug 27;56(9):
pubmed: 29899003